RE: Interesting 170k buy 11p14 Nov 2025 11:24
The clock is ticking. Key updates in 2025 regarding a potential deal:
Active Discussions ImmuPharma is currently in active discussions with a number of potential global commercial partners for its lead P140 platform.
End-of-Year Objective The company has stated its objective to complete a partnership deal by the end of 2025.
Data Room A comprehensive data room is available for potential partners to conduct due diligence under a Confidential Disclosure Agreement (CDA).
Patent Protection A new groundbreaking patent application for P140 was filed in September 2025, which could extend intellectual property protection until 2045, strengthening the commercial appeal of the asset.
Financial Position The company has extended its cash runway into the second half of 2026 and has stated it intends to use the proceeds from a potential deal to further strengthen its cash position, indicating the deal is a primary focus for non-dilutive funding.
Scientific Progress Throughout 2025, ImmuPharma has released updates on the unique mechanism of action (MOA) of P140, including the development of a companion diagnostic to identify patients most likely to respond, which enhances the platform's value to potential partners.